From Sample to Insight: Streamline Your Oncology Research with Ion GeneStudio S5 systems and Oncomine Assays

While tissue NGS is the standard for gaining insights into the biology of a tumor, liquid biopsy–based NGS is emerging as a highly sensitive method to understand resistance mechanisms as a tumor evolves. Liquid biopsies are minimally invasive and may be used as an alternative when tissue samples are not available. Moreover, liquid biopsy testing may complement tissue testing to better understand inter- and intra-tumor heterogeneity. Ion Torrent Oncomine cell-free assays can help lead to important insights from liquid samples, including blood, bile, cerebrospinal fluid, and urine.

• A broad range of NGS assays for research applications across multiple solid tumor types
• Easy, fast, and automated workflows to help minimize hands‑on time and maximize efficiency
• Integrated data analysis and reporting tools for easy data interpretation

Homologous recombination deficiency (HRD) is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-stranded breaks using the homologous recombination repair (HRR) pathway. HRD is becoming more relevant in research applications, especially in ovarian, breast, prostate, and pancreatic cancers because of HRD-positive tumors are sensitive to platinum analogs and poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, a class of anticancer agents that exhibit synthetic lethality when applied to cells defective in the HRR pathway.

Oncomine assays provide tools for identifying both causes and consequences of HRD.

• Complete end-to-end NGS workflows for precision oncology research
• Low sample input requirements help ensure smaller samples, and thus more samples can be tested
• Highly automated with a complete bioinformatics solution, including reporting, to empower HRD assessment in your laboratory

Explore our comprehensive portfolio of NGS testing solutions designed to enhance your understanding of hematological malignancies. Our assays support multiple research applications for the analysis of myeloid and lymphoid malignancy samples.

• Rapid and comprehensive detection—detect multiple relevant and novel alterations from DNA and RNA inputs, with results typically available in just 3 days
• Efficient workflows—easily transition from sample to annotated variant report with our integrated and automated workflows, significantly reducing hands-on time
• An extensive assay menu—access a broad selection of assays tailored for key hemato-oncology genomic profiling applications, meeting all the needs of your laboratory

Ion Torrent Oncomine immune repertoire research assays offer a robust suite of solutions for profiling the immune repertoire. They offer highly sensitive NGS capabilities to accurately assess clonality and detect biomarkers associated with MRD across various lymphoid malignancy sample types.

• Increase clone detection—sequence multiple B cell and T cell receptor targets in a single reaction to enhance clone detection rates
• Ultrasensitive analysis—identify rare clones for MRD analysis with an ultralow LOD down to 10^–6
• Precise SHM measurement—accurately measure the level of somatic hypermutation (SHM) in immunoglobulin heavy chain variable (IGHV) genes, leveraging the ultralow substitution error rate of Ion GeneStudio S5 systems